Piramal’s Critical Care Division to Acquire Janssen Assets

Piramal Enterprises’ wholly owned Critical Care subsidiary in the UK has entered into an agreement to acquire five anesthesia and pain management injectable products from Janssen Pharmaceutica NV, for $155 million upfront in cash, and as much as an additional $20 million. The products include five injectable versions of Janssen’s, Sublimaze (fentanyl citrate), Sufenta (sufentanil citrate), Rapifen (alfentanil hydrochloride), Dipidolor (piritramide), and Hypnomidate (etomidate), which are currently marketed in more than 50 countries.
 
Piramal will acquire the brand names and related IP, including how to make both the API and the finished dosage forms of the products. The potential acquisition does not include the transfer of any manufacturing facilities or employees.
 
Janssen will continue to supply finished dosage forms for up to three years and API for up to five years. Janssen will continue to sell the products on behalf of Piramal until the marketing authorizations or relevant business relations are transferred to Piramal.
 
Ajay Piramal, chairman, Piramal Enterprises said, “Healthcare is an important focus area for Piramal Enterprises and we are strongly committed to growing this segment. This acquisition is critical in shaping our product offerings, providing access to global markets and leveraging our existing capabilities. This acquisition is an important step in enabling Piramal Critical Care to start to address the global generic injectable hospital drug market which is greater than $20 billion in size.”